Biotech News

BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting

BioCryst Pharmaceuticals (BCRX)BioCryst PharmaceuticalsCompany update

— Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who initiated or switched to ORLADEYO ® from another prophylactic therapy — RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.

Related news

BCRXBioCryst Pharmaceuticals2026-10-29 11:00 EST

BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting

BCRXBioCryst Pharmaceuticals2026-10-05 11:00 EST

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

PHVSPharvaris2026-10-29 10:50 EST

Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting

RHHBYRoche Holdings AG2026-10-23 17:30 EST

Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

JNJJohnson & Johnson2026-10-19 12:23 EST

Johnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn’s disease and expanding evidence in perianal fistula

MNPRMonopar2026-11-09 13:00 EST

Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026

ARWRArrowhead Pharmaceuticals2026-11-07 21:15 EST

Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates

RHHBYRoche Holdings AG2026-11-10 06:00 EST

Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer’s disease portfolio at CTAD 2026

ARWRArrowhead Pharmaceuticals2026-11-02 12:30 EST

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

MGTXMeiraGTx2026-10-27 12:00 EST

MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting

BioCryst Pharmaceuticals

Rare-Disease Drug Development BioCryst Pharmaceuticals discovers, develops and commercializes small-molecule medicines for rare diseases. Its portfolio combines a marketed hereditary angioedema franchise with clinical programs targeting additional protein-mediated disorders. ORLADEYO Commercial Franchise ORLADEYO is an oral preventive...

Recent company news

Stock data

Close
7.32 USD
Market cap
2.12B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States